News Daily News Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds Michael O'Riordan April 25, 2025
News Daily News Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations L.A. McKeown January 31, 2025
News Daily News BMI Mostly Doesn’t Impact DOACs, Except Maybe at the Extremes Todd Neale February 02, 2024
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Daily News New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF L.A. McKeown April 19, 2023
News Opinion Editor's Corner AHA 2021 AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More Shelley Wood November 08, 2021
News Daily News Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines Todd Neale January 29, 2019
News Daily News Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina Michael O'Riordan June 30, 2016
News Daily News FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin Michael O'Riordan June 30, 2016
News Daily News Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER Michael O'Riordan June 14, 2016
News Daily News Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular Michael O'Riordan June 14, 2016